-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

462 Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Program: Oral and Poster Abstracts
Type: Oral
Session: 613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies
Hematology Disease Topics & Pathways:
AML, Diseases, Hemoglobinopathies, Technology and Procedures, Myeloid Malignancies, Clinically relevant, molecular testing
Sunday, December 6, 2020: 3:00 PM

Maël Heiblig, MD1*, Hélène Labussière, MD2*, Marie Virginie Larcher, MD3*, Gaelle Fossard, MD4*, Marie Balsat, MD4*, Sophie Ducastelle, MD2*, Sandrine Loron, MD2*, Sandrine Hayette, PhD5*, Sarah Huet6*, Pierre Sujobert, MD, PhD7*, Fiorenza Barraco, MD8*, Xavier Thomas, MD, PhD9, Alice Marceau10*, Delphine Lebon, MD11*, Laure Goursaud12*, Isabelle Plantier, MD13*, Laure Stalnikiewich14*, Cecile Frimat15*, Nathalie Cambier16*, Nicolas Duployez, PharmD, PhD17*, Herve Ghesquieres, MD, PhD18* and Claude Preudhomme, MD, PhD19

1Centre Hospitalier Lyon Sud, Lyon, FRA
2Hematology department 1 G, Centre Hospitalier Lyon Sud, Pierre Benite, France
3Lyon Sud Hospital, Pierre Bénite, France
4Hematology, Centre Hospitalier Lyon Sud, Pierre Benite, France
5Centre Hospitalier Lyon Sud, Pierre Benite, FRA
6Centre Hospitalier Universitaire de Lyon, Lyon, France
7Laboratory of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
8Centre Hospitalier Universitaire Lyon Sud, Lyon, France
9Department of Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, Lyon, France
10Centre de Biologie-Pathologie, CHU Lille, Lille, France
11CHU Amiens Picardie Hôpital, Amiens, France
12Service des Maladies du sang, CHRU Lille, Lille, France
13Service d'hématologie clinique, CH Roubaix, Roubaix, France
14Département Hématologie, CH Lens, Lens, France
15CHRU Lille, Lille, France
16Cytologie, CH Valenciennes, Valencienne, France
17Laboratory of Hematology, Centre Hospitalier Universitaire Lille, Lille, France
18Department of Hematology, Centre Hospitalier Lyon-Sud, University Claude Bernard Lyon 1, Pierre Benite, France
19ALFA Group, Paris, France

Minimal residual disease is now a powerfull surrogate marker to assess response to chemotherapy in acute myeloid leukemia (AML). In younger adults, NPM1 MRD has recently demonstrated to be a favorable predictive marker for EFS and OS independently of fms-like tyrosine kinase-3 internal tandem duplications (FLT3-ITD) status. However, there is very few datas regarding predictive value of NPM1 MRD in elderly patients treated with intensive chemotherapy. Moreover, numerous studies have suggested the negative impact of DNMT3a mutation in NPM1 AML patients, especially in those with concurrent FLT3-ITD mutation. In this study, we aimed to investigate the impact of DNMT3a status on post induction NPM1 MRD1 predictive value for survival in a retrospective cohort of AML patients aged over 60 years old treated intensively.

A total of 138 patients treated for NPM1 mutated AML in two French institutions (Lyon, Lille) were analyzed retrospectively. Median age of the entire cohort was 66.1 years old (range 60-78.2). An FLT3-ITD mutation was evidenced in 52 of 138 patients (37.6%) with a median FLT3-ITD AR of 0.53 (range, 0.05-3). With a median follow-up of 19.61 months (0.07-128.4), the overall CR rate was 89.9% with no influence of DNMT3a or FLT3 mutational status on the probability of CR. In this elderly cohort of NPM1mut patients, a 4log reduction of NPM1 bone marrow (BM) MRD1 was associated with better outcome (median OS: NR vs 13.4 months, HR=0.35, p<0.01)(Figure A). Overall, DNMT3 status did not influence the probability of having a ≥ 4log MRD1 reduction after induction. However, only 9/44 (20.4%) FLT3-ITD patients reached ≥ 4log MRD1 reduction whereas 38/80 FLT3wt (47.5%) were good molecular responders (p<0.001). FLT3-ITD mutated patients who achieved a 4log reduction had a superior outcome compared to those who did not (HR=0.34; 95% CI, 0.16 to 0.70; P <0.001). Similarly, NPM1mut FLT3wt patients with a 4log reduction in NPM1 BM-MRD1 had a longer OS (3-year OS, 68.1%; 95% CI, 48.8 to 82.9) than those without good molecular response (3-year OS, 46.5%; 95% CI, 30.2 to 61.7)(Figure B). DNMT3a negative patients who achieved a 4log reduction had a superior outcome to those who did not reached at least a 4log reduction (HR=0.23; 95% CI, 0.07 to 0.72; P <0.001). However, postinduction NPM1 MRD1 reduction was not predictive of OS and leukemia free survival (LFS) in DNMT3amut patients. DNMT3amut patients has a very poor LFS which was even worst in poor NPM1 MRD1 responders compared to those who reached at least 4log reduction (median LFS: 8.3 months vs 17.4 months, HR = 0.48, 95% CI, 0.25-0.91, p=0.023)(Figure C). In multivariate analysis, only DNMT3a mutational status and a 4-log reduction in NPM1 BM-MRD were significantly associated with survival. Based on these results, we identified among NPM1 positive patients 3 groups with distinct prognosis, based on FLT3-ITD, DNMT3a status and NPM1 BM-MRD post induction response (NPM1 scoring system)(Figure D). When compared to ELN 2017 intermediate risk group (AUC=0.695), NPM1 scoring system (NPM1 SS) was more accurate for OS prediction in patients within intermediate (AUC=0.833) and unfavorable (AUC=0.863) NPM1 SS risk group. However, there was no significant difference in AUC between NPM1 SS favorable and ELN 2017 favorable risk group.

These results confirm that post-induction NPM1 MRD1 is a reliable tool to assess disease outcome in elderly AML patients. However, the presence of DNMT3a also identify a subgroup of patients at very high risk of relapase, despite good molecular responses. As hematopoietic stem cell transplantation (HSCT) might improve OS in elderly patients, DNMT3a positive AML elderly patients should be considered for HSCT or post induction maintenance strategies, even within the favorable ELN risk group.

Disclosures: Sujobert: Gilead/Kyte: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sunesis: Research Funding.

*signifies non-member of ASH